We further demonstrate the clinically relevant potential of GSK-3 inhibitors as antileukemic agents and extend the field of application of such agents. Indeed, although APL patients benefit ...
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
Hepatitis B affects almost 300 million people worldwide, according to GSK, and while nucleoside/nucleotide analogue (NA) drugs to treat it are available – such as Gilead’s polymerase inhibitor ...
GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...
Zacks.com on MSN3mon
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary GoalsDepemokimab is an inhibitor of IL-5 ... for treating eosinophilic granulomatosis with polyangiitis. GSK has a Zacks Rank #3 ...
The tyrosine kinase inhibitor (TKI ... leads to about 43% of patients experiencing grade 3 or greater toxicity, are a driving part of GSK’s interest in IDRx. The pharma was looking for a ...
GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab ... with an average gain of +24.3% per year. So be sure to give ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback